Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2017 Jan 26;1(1):CD007417.
doi: 10.1002/14651858.CD007417.pub3.

Corticosteroids as adjuvant therapy for ocular toxoplasmosis

Smitha Jasper  1 , Satyanarayana S Vedula  2 , Sheeja S John  1 , Saban Horo  1 , Yasir J Sepah  3 , Quan Dong Nguyen  3
Affiliations

Corticosteroids as adjuvant therapy for ocular toxoplasmosis

Smitha Jasper et al. Cochrane Database Syst Rev. .

Abstract

Background: Ocular infection caused by Toxoplasma gondii, a parasite, may result in inflammation in the retina, choroid, and uvea, and consequently lead to complications such as glaucoma, cataract, and posterior synechiae.

Objectives: The objective of this systematic review was to assess the effects of adjunctive use of corticosteroids to anti-parasitic therapy versus anti-parasitic therapy alone for ocular toxoplasmosis.

Search methods: We searched CENTRAL (which contains the Cochrane Eyes and Vision Trials Register (2016; Issue 11)), MEDLINE Ovid, Epub Ahead of Print, In-Process & Other Non-Indexed Citations, MEDLINE Ovid Daily (January 1946 to December 2016), Embase (January 1980 to December 2016), Latin American and Caribbean Literature on Health Sciences (LILACS (January 1982 to December 2016)), the ISRCTN registry (www.isrctn.com/editAdvancedSearch), ClinicalTrials.gov (www.clinicaltrials.gov), and the World Health Organization (WHO) International Clinical Trials Registry Platform (ICTRP; www.who.int/ictrp/search/en). We used no date or language restrictions in the electronic searches for trials. We last searched the electronic databases on 7 December 2016.

Selection criteria: We had planned to include randomized and quasi-randomized controlled trials. Eligible trials would have enrolled participants of any age who were immunocompetent and were diagnosed with acute ocular toxoplasmosis. Included trials would have compared anti-parasitic therapy plus corticosteroids versus anti-parasitic therapy alone, different doses or times of initiation of corticosteroids.

Data collection and analysis: Two authors independently screened titles and abstracts retrieved through the electronic searches. We retrieved full-text reports of studies categorized as 'unsure' or 'include' after we reviewed the abstracts. Two authors independently reviewed each full-text report for eligibility. Discrepancies were resolved through discussion.

Main results: We identified no completed or ongoing trial that was eligible for this Cochrane review.

Authors' conclusions: Although research has identified a wide variation in practice regarding the use of corticosteroids, our review did not identify any evidence from randomized controlled trials for or against the role of corticosteroids in the management of ocular toxoplasmosis. Several questions remain unanswered by well-conducted randomized trials in this context, including whether the use of corticosteroids as an adjunctive agent is more effective than the use of anti-parasitic therapy alone; if so, when corticosteroids should be initiated in the treatment regimen (early versus late course of treatment), and what would be the best dose and duration of steroid use.

PubMed Disclaimer

Conflict of interest statement

SJ: none known. SSV: none known. SSJ: none known. SH: none known. YJS: none known. QDN: none known.

Figures

1
1
Study flow diagram
See this image and copyright information in PMC

Update of

References

References to studies excluded from this review

Acers 1964 {published data only}
    1. Acers TE. Toxoplasmosis retinochoroiditis: a double blind therapeutic study. Archives of Ophthalmology 1964;71(1):58‐62. - PubMed
Apt 1978 {published data only}
    1. Apt W. Treatment of toxoplasmosis. Revista Medica De Chile 1978;106(8):622‐5. - PubMed
Arseni 1979 {published data only}
    1. Arseni C, Ciurea V, Horvath L. Possibilities of preventing and combating congenital toxoplasmosis. Revista De Medicina‐Interna, Neurologie, Psihiatrie, Neurochirurgie, Dermato‐Venerologie 1979;24(4):251‐7. - PubMed
Atias 1966 {published data only}
    1. Atías A, Pasmanik S, Niedmann G. An analysis of the treatment and evolution of 56 cases of ocular toxoplasmosis. Boletin Chileno De Parasitologia 1966;21(4):108‐11. - PubMed
Baharivand 2013 {published data only}
    1. Baharivand N, Mahdavifard A, Fouladi RF. Intravitreal clindamycin plus dexamethasone versus classic oral therapy in toxoplasmic retinochoroiditis: a prospective randomized clinical trial. International Ophthalmology 2013;33(1):39‐46. - PubMed
Balaskas 2012 {published data only}
    1. Balaskas K, Vaudaux J, Boillat‐Blanco N, Guex‐Crosier Y. Azithromycin versus sulfadiazine and pyrimethamine for non‐vision‐threatening toxoplasmic retinochoroiditis: A pilot study. Medical Science Monitor 2012;18(5):CR296‐302. - PMC - PubMed
Bethge 1971 {published data only}
    1. Bethge H. Alternating corticoid therapy. Deutsche Medizinische Wochenschrift 1971;96(30):1254‐9. - PubMed
Bosch‐Driessen 1988 {published data only}
    1. Bosch‐Driessen EH, Rothova A. Sense and nonsense of corticosteroid administration in the treatment of ocular toxoplasmosis. British Journal of Ophthalmology 1998;82(8):858‐60. - PMC - PubMed
Bouree 1997 {published data only}
    1. Bouree P, Romand S, Majoube A. Liver transplantation and toxoplasmosis: Serological follow‐up of 34 patients [Transplantation hepatique et toxoplasmose: Suivi serologique de 34 patients]. Medecine et Chirurgie Digestives 1997;26(4):173‐4.
Coles 1966 {published data only}
    1. Coles RS. Steroid therapy in uveitis. International Ophthalmology Clinics 1966;6(4):869‐901. - PubMed
Concha 2000 {published data only}
    1. Concha M, Rabinstein A. Central nervous system opportunistic infections in HIV‐1 infection. CNS Spectrums 2000;5(4):43‐60. - PubMed
Couvreur 1983 {published data only}
    1. Couvreur J, Desmonts C. Treatment of congenital toxoplasmosis. Zentralblatt fur Gynakologie 1983;105(17):1108‐12. - PubMed
Couvreur 1985 {published data only}
    1. Couvreur J, Bloch‐Michel E. Ocular toxoplasmosis: preventive and therapeutic measures. Medecine et Hygiene 1985;43(1616):2216‐20.
Djurkovic‐Djakovic 1995 {published data only}
    1. Djurkovic‐Djakovic O, Stanojevic‐Paovic A, Bobic B, Bergam J, Nikolic A, Paovic J, et al. Short‐term effects of the clindamycin‐steroid regimen in the treatment of ocular toxoplasmosis. Journal of Chemotherapy 1995;7 Suppl 4:199‐201. - PubMed
Giles 1966 {published data only}
    1. Giles CL. The treatment of toxoplasmic posterior uveitis (chorioretinitis). American Journal of the Medical Sciences 1966;251(2):241‐2. - PubMed
Gordon 1970 {published data only}
    1. Gordon DM. The treatment of toxoplasmic uveitis. International Ophthalmology Clincs 1970;10(3):639‐46. - PubMed
Hay 1997 {published data only}
    1. Hay J, Dutton GN. How should active toxoplasmic retinochoroiditis be treated?. Eye 1997;11(Pt 6):767‐70. - PubMed
Nolan 1968 {published data only}
    1. Nolan J, Rosen ES. Treatment of active toxoplasmic retino‐choroiditis. British Journal of Ophthalmology 1968;52(5):396‐9. - PMC - PubMed
O'Connor 1974 {published data only}
    1. O'Connor GR. Manifestations and management of ocular toxoplasmosis. Bulletin of the New York Academy of Medicine 1974;50(2):192‐210. - PMC - PubMed
O'Connor 1976 {published data only}
    1. O'Connor GR, Frenkel JK. Dangers of steroid treatment in toxoplasmosis. Periocular injections and systemic therapy. Archives of Ophthalmology 1976;94(2):213. - PubMed
Reibaldi 1989 {published data only}
    1. Reibaldi A, Cavallaro N, Santocono M, Scuderi A. Up‐date on the treatment of ocular toxoplasmosis. Journal of Chemotherapy 1989;1 Suppl 4:954‐6. - PubMed
Sherman 1992 {published data only}
    1. Sherman MD, Nozik RA. Other infections of the choroid and retina. Toxoplasmosis, histoplasmosis, Lyme disease, syphilis, tuberculosis and ocular toxocariasis. Infectious Disease Clinics of North America 1992;6(4):893‐908. - PubMed
Unknown author 1968 {published data only}
    1. Anonymous. Toxoplasmosis. Medical Letter on Drugs and Therapeutics 1968;10(26):107‐8. - PubMed

Additional references

Anderson 1979
    1. Anderson S. Toxoplasma gondii. In: Mandell Gl, Douglas RG Jr, Bennet JE editor(s). Principles and Practice of Infectious Diseases. New York: John Wiley and Sons, 1979.
Benzina 2005
    1. Benzina Z, Chaabouni S, Hentati N, Trigui A, Chaabouni F, Ben Salah S, et al. Recurrent toxoplasmic retinochoroiditis after clindamycin treatment. Journal Francais d'Ophthalmologie 2005;28(9):958‐64. - PubMed
Bloch‐Michel 1987
    1. Bloch‐Michel E, Nussenblatt RB. International Uveitis Study Group recommendations for the evaluation of intraocular inflammatory disease. American Journal of Ophthalmology 1987;103(2):234‐5. - PubMed
Bosch‐Driessen 2002
    1. Bosch‐Driessen LH, Verbraak FD, Suttorp‐Schulten MS, Ruyven RL, Klok AM, Hoyng CB, et al. A prospective, randomized trial of pyrimethamine and azithromycin vs pyrimethamine and sulfadiazine for the treatment of ocular toxoplasmosis. American Journal of Ophthalmology 2002;134(1):34‐40. - PubMed
Damms 1993
    1. Damms T, Bohnke M, Behrend‐Berdin B. Results of therapy in ocular toxoplasmosis. Comparison of various forms of therapy. Ophthalmologe 1993;90(6):737‐41. - PubMed
Dodds 2008
    1. Dodds EM, Holland GN, Stanford MR, Yu F, Siu WO, International Ocular Toxoplasmosis Research Group. Intraocular inflammation associated with ocular toxoplasmosis: relationships at initial examination. American Journal of Ophthalmology 2008;146(6):856‐65. - PubMed
Fine 1981
    1. Fine SL, Owens SL, Haller JA, Knox DL, Patz A. Choroidal neovascularization as a late complication of ocular toxoplasmosis. American Journal of Ophthalmology 1981;91(3):318‐22. - PubMed
Folk 1984
    1. Folk JC, Lobes LA. Presumed toxoplasmis papillitis. Ophthalmology 1984;91(1):64‐7. - PubMed
Gilbert 1999
    1. Gilbert RE, Dunn DT, Lightman S, Murray PI, Pavesio CE, Gormley PD, et al. Incidence of symptomatic toxoplasma eye disease: aetiology and public health implications. Epidemiology and Infection 1999;123(2):283‐9. - PMC - PubMed
Glanville 2006
    1. Glanville JM, Lefebvre C, Miles JN, Camosso‐Stefinovic J. How to identify randomized controlled trials in MEDLINE: ten years on. Journal of the Medical Library Association 2006;94(2):130‐6. - PMC - PubMed
Guldsten 1983
    1. Guldsten H. Clindamycin and sulphonamides in the treatment of ocular toxoplasmosis. Acta Ophthalmologica 1983;61(1):51‐7. - PubMed
Hegab 2003
    1. Hegab SM, Al‐Mutawa SA. Immunopathogenesis of toxoplasmosis. Clinical and Experimental Medicine 2003;3(2):84‐105. - PubMed
Higgins 2011a
    1. Higgins JP, Altman DG, Sterne JAC editor(s). Chapter 8: Assessing risk of bias in included studies. In: Higgins JP, Green S editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org.
Higgins 2011b
    1. Higgins JP, Deeks JJ, Altman DG editor(s). Chapter 16: Special topics in statistics.in: Higgins JP, Green S editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org.
Hogan 1959
    1. Hogan MJ, Kimura SJ, Thygeson P. Signs and symptoms of uveitis. I. Anterior uveitis. American Journal of Ophthalmology 1959;47(5, Pt 2):155‐70. - PubMed
Holland 2002
    1. Holland GN, Lewis KG. An update on current practices in the management of ocular toxoplasmosis. American Journal of Ophthalmology 2002;134(1):102‐14. - PubMed
Kaufman 1960
    1. Kaufman HE. The effect of corticosteroids on experimental ocular toxoplasmosis. American Journal of Ophthalmology 1960;50:919‐26. - PubMed
Kim 2012
    1. Kim SJ, Scott IU, Brown GC, Brown MM, Ho AC, Ip MS, et al. Interventions for toxoplasma retinochoroiditis: a report by the American Academy of Ophthalmology. Ophthalmology 2013;120(2):371‐8. - PubMed
Kishore 2001
    1. Kishore K, Conway MD, Peyman GA. Intravitreal clindamycin and dexamethasone for toxoplasmic retinochoroiditis. Ophthalmic Surgery and Lasers 2001;32(3):183‐92. - PubMed
Klaren 2002
    1. Klaren VN, Kijlstra A. Toxoplasmosis, an overview with emphasis on ocular involvement. Ocular Immunology and Inflammation 2002;10(1):1‐26. - PubMed
Lam 1993
    1. Lam S, Tessler HH. Quadruple therapy for ocular toxoplasmosis. Canadian Journal of Ophthalmology 1993;28(2):58‐61. - PubMed
Lum 2005
    1. Lum F, Jones JL, Holland GN, Liesegang TJ. Survey of ophthalmologists about ocular toxoplasmosis. American Journal of Ophthalmology 2005;140(4):724‐6. - PubMed
Mittelviefhaus 1992
    1. Mittelviefhaus H. Therapy of ocular toxoplasmosis with clindamycin. Klinische Monatsblätter für Augenheilkunde 1992;200(2):123‐7. - PubMed
Nozik 1977
    1. Nozik RA. Results of treatment of ocular toxoplasmosis with injectable corticosteroids. Transactions. Section on Ophthalmology. American Academy of Ophthalmology and Otolaryngology 1977;83(5):811‐8. - PubMed
Nussenblatt 1985
    1. Nussenblatt RB, Palestine AG, Chan CC, Roberge F. Standardization of vitreal inflammatory activity in intermediate and posterior uveitis. Ophthalmology 1985;92(4):467‐71. - PubMed
Papadia 2011
    1. Papadia M, Aldigeri R, Herbort CP. The role of serology in active ocular toxoplasmosis. International Ophthalmology 2011;31(6):461‐5. - PubMed
Parmar 1998
    1. Parmar MK, Torri V, Stewart L. Extracting summary statistics to perform meta‐analyses of the published literature for survival endpoints. Statistics in Medicine 1998;17(24):2815‐34. - PubMed
Pradhan 2016
    1. Pradhan E, Bhandari S, Gilbert RE, Stanford M. Antibiotics versus no treatment for toxoplasma retinochoroiditis. Cochrane Database of Systematic Reviews 2016, Issue 5. [DOI: 10.1002/14651858.CD002218.pub2] - DOI - PMC - PubMed
Psilas 1990
    1. Psilas K, Petroutsos G, Aspiotis M. Treatment of toxoplasmosis. The treatment of toxoplasmic chorioretinitis. Journal Francais d'Ophthalmologie 1990;13(11‐12):551‐3. - PubMed
Raskin 2002
    1. Raskin E, Alves M, Eredia GC, Raskin A, Ruiz Alves M. Ocular toxoplasmosis: A comparative study of the treatment with sulfadiazine and pyrimetamine versus sulphametoxazole‐trimethoprim. Revista Brasileira De Oftalmologia 2002;61(5):335‐8.
Rothova 1989
    1. Rothova A, Buitenhuis HJ, Meenken C, Baarsma GS, Boen‐Tan TN, Jong PT, et al. Therapy of ocular toxoplasmosis. International Ophthalmology 1989;13(6):415‐9. - PubMed
Rush 2012
    1. Rush R, Sheth S. Fulminant toxoplasmic retinochoroiditis following Intravitreal triamcinolone administration. Indian Journal of Ophthalmology 2012;60(2):141‐3. - PMC - PubMed
Sabates 1981
    1. Sabates R, Pruett RC, Brockhurst RJ. Fulminant ocular toxoplasmosis. American Journal of Ophthalmology 1981;92(4):497–503. - PubMed
Schünemann 2011
    1. Schünemann HJ, Oxman AD, Higgins JP, Vist GE, Glasziou P, Guyatt GH. Chapter 11: Presenting results and ‘Summary of findings' tables. in: Higgins JP, Green S editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org.
Soheilian 2005
    1. Soheilian M, Sadoughi MM, Ghajarnia M, Deghan MH, Behboudi H, Anisian A, et al. Prospective randomized trial of trimethoprim/sulfamethoxazole versus pyrimethamine and sulfadiazine in the treatment of ocular toxoplasmosis. Ophthalmology 2005;112(11):1876‐82. - PubMed
Timsit 1987
    1. Timsit JC, Bloch‐Michel E. Efficacy of specific chemotherapy in the prevention of recurrences of toxoplasmic chorioretinitis during the 4 years following the treatment. Journal Francais d'Opthalmologie 1987;10(1):15‐23. - PubMed

References to other published versions of this review

Jasper 2013
    1. Jasper S, Vedula SS, John SS, Horo S, Sepah YJ, Nguyen QD. Corticosteroids as adjuvant therapy for ocular toxoplasmosis. Cochrane Database of Systematic Reviews 2013, Issue 4. [DOI: 10.1002/14651858.CD007417.pub2] - DOI - PMC - PubMed
Vedula 2008
    1. Vedula SS, Nguyen QD. Corticosteroids for ocular toxoplasmosis. Cochrane Database of Systematic Reviews 2008, Issue 4. [DOI: 10.1002/14651858.CD007417] - DOI - PMC - PubMed

Publication types

MeSH terms

Substances